. Stay informed about the country's evolving healthcare landscape.){kind=link}
China Scientific Machine is excited to announce the addition of innovative medications to the Nationwide Repayment Drug Listing! VALTOCO (Diazepam Nasal Spray), ILUMETRI (Tildrakizumab Injection), and Tetrabenazine Pills for rare diseases have been newly integrated in the NRDL, and XinHuoSu continues to be included as well.
China Scientific Machine has been actively working to promote innovative products and respond to national policies. This has resulted in the integration of three licensed innovative medications: Diazepam Nasal Spray, Tildrakizumab Injection, and Methotrexate Injection-psoriasis in the NRDL. This will greatly improve patient access and affordability of these medications.
The inclusion of these products in the NRDL will expand their market coverage and increase their official label power, positively impacting CMS’s business strategy.
Exciting news from China Scientific Machine Holdings Limited! Diazepam Nasal Spray (VALTOCO), Tildrakizumab Injection (ILUMETRI), and rare disease drug Tetrabenazine Pills have been newly integrated into China’s Nationwide Repayment Drug Listing. Furthermore, Recombinant Human Mind Natriuretic Peptide for Injection (XinHuoSu) will continue to be part of the listing, effective from January 1, 2024. Additionally, Methotrexate Injection (Metoject) for psoriasis has been included in class A of the Nationwide Repayment Drug Listing.
Product Highlights:
VALTOCO (Diazepam Nasal Spray)
VALTOCO was licensed for advertising in China in June 2023. It is the first nasal spray formula of diazepam in China and is indicated for the treatment of seizure clusters. VALTOCO has a unique combination of Vitamin E-based solvents and Intravail® absorption enhancer, which allows for non-invasive delivery and rapid onset of action.